Navigation Links
Caldolor® Clinical Study in Hospitalized Burn Patients Published in Journal of Burn Care & Research
Date:5/16/2011

NASHVILLE, Tenn., May 16, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced that results from a clinical study evaluating the safety and efficacy of Caldolor® (ibuprofen) Injection in treating fever and pain in hospitalized burn patients was published in Volume 32, Number 1 of the Journal of Burn Care & Research. The study demonstrated that Caldolor significantly reduces fever in these patients, including those with severe thermal burns. The newly published study also supports the safety of Caldolor as it involved the highest dose and duration of exposure to IV ibuprofen to date, demonstrating that the recommended maximum daily dose of 3200mg/day over five days of treatment was well tolerated.

"Immediate and sustained regulation of body temperature and reduction of fever following a burn injury is critical to patient recovery as well as comfort," said Dr. John T. Promes, principal investigator of the study, Director of Trauma Services and Associate Director for Surgical Education at Orlando Regional Medical Center, Assistant Professor of Surgery at the University of Central Florida College of Medicine, and Clinical Assistant Professor in the Department of Surgery at the Florida State University College of Medicine. "Because oral administration of antipyretics in hospitalized burn patients is often impossible due to sedation, intubation and a variety of factors, IV fever reduction with an agent such as Caldolor is not only convenient but often necessary. Further, as a non-steroidal anti-inflammatory drug (NSAID), Caldolor has the potential to arrest the cascade of inflammation caused by burn injury and thereby alleviate pain in addition to fever."

The prospective, multicenter, randomized, double-blind, placebo-controlled trial was conducted at five U.S. and international sites, including hospital burn units and burn centers. The study evaluated 61 adult burn patients with second or third degree burns covering more than 10 percent total body surface area with an anticipated hospital stay of more than 72 hours and fever evidenced by temperatures of 38.0 degrees C (100.4 degrees F) or greater. Patients were administered 800mg of Caldolor every six hours for five consecutive days. The primary efficacy endpoint of the study was to reduce fever as measured by area under the curve for temperature (AUC-T degrees) over the first 24 hours of treatment, compared with a target temperature of 37.0 degrees C (98.6 degrees F). Statistical significance was achieved for the primary endpoint of the study, as there was a significant reduction in temperature (AUC-T degrees, 0-24 hours) in patients receiving Caldolor compared with those receiving placebo (p=0.008). Caldolor was well tolerated and there was no significant difference in adverse events between patients receiving placebo and those receiving Caldolor.

"The publication of this study supports hospital physicians' ability to rely on Caldolor to treat burn patients, who often suffer from both fever and pain," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "These study results supporting use of Caldolor to treat fever in this patient population offer strong evidence of both efficacy and safety, and the product stands to help thousands of patients suffering from severe burns."

According to the American Burn Association, 1.1 million burn injuries require medical attention each year in the United States. Of these, approximately 50,000 burn injuries require hospitalization, 20,000 are major burn injuries affecting 25 percent of total body surface area and 4,500 people die. In addition, up to 10,000 people in the United States die every year from burn-related infections.(1)

About Caldolor

Caldolor is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, and for the reduction of fever in adults. It is the first FDA approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticaria, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment with Caldolor. For full prescribing information, including boxed warning, visit www.caldolor.com.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's marketed products include Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, and Kristalose® (lactulose) for Oral Solution, a prescription laxative. Cumberland is dedicated to providing innovative products which improve quality of care for patients. For more information, visit the Company's website at www.cumberlandpharma.com.

Important Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that reflect Cumberland's current views on future events, based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of operations are subject to influences outside of the Company's control. Risk factors that could materially affect results of operations include market conditions, competition from existing and new products, an inability or failure of manufacturers to produce the Company's products on a timely basis or to comply with stringent regulations applicable to drug manufacturers, maintaining and building an effective sales and marketing infrastructure, government regulation, the possibility that patent rights may provide limited protection from competition, and other factors including those under the headings "Risk factors" and "Management's discussion and analysis of financial condition and results of operations" in Cumberland's Form 10-K filed with the SEC on March 11, 2011. There can be no assurance that results anticipated by Cumberland will be realized or, if realized, that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. Cumberland undertakes no obligation to release publicly any revisions to these statements to reflect events or circumstances after the date hereof.

References

(1) American Burn Association (2002). Burn Incidence Fact Sheet.


'/>"/>
SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anesthesiologists Use Caldolor® To Provide Preemptive Pain Control for Surgical Patients at U.S. Medical Centers
2. Caldolor® Rapid Infusion Shown to be Safe and Well Tolerated in Newly Published Clinical Study
3. Newly Published Data Demonstrates Caldolor® Significantly Reduces Pain and Morphine Use in Post-Operative Patients
4. Caldolor® (ibuprofen) Injection Gaining Approval on Formulary at U.S. Medical Centers
5. Pre and Post-Operative Use of Caldolor® (Ibuprofen) Injection Significantly Reduces Pain and Opioid Use in Newly Published Study
6. Latest Clinical Evidence Supports Promising Outlook for Low-Dose Molecular Breast Imaging (MBI)
7. Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan
8. CrystalGenomics Completes Phase I MAD Study of its Novel Antibiotic Candidate CG400549, and Prepares for Phase II Clinical Study
9. Amira Pharmaceuticals to Present Preclinical Data on AM152 , an LPA1 Receptor Antagonist, at the Annual Meeting of the American Thoracic Society
10. Medco Research Institute® and AssureRx Health Initiate Pilot Program to Evaluate Adoption and Clinical Impact of Pharmacogenetic Testing for Selection of Psychotropic Medications
11. MedQuist Awarded Clinical Documentation Outsource Contract for St. Josephs Hospital Health Center With Focus on Cost Savings, Quality, Peace of Mind
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... Tenn. and DALLAS , April 19, 2017 ... announced that the first patients in Nashville ... device in the Lower Esophageal Sphincter Stimulation for GERD ... implantable device designed to provide long-term reflux control by ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... SAN DIEGO , April 19, 2017 /PRNewswire/ ... ("Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new ... today announced the closing of its previously announced ... common stock at a public offering price of ... commissions and estimated offering expenses payable by Sorrento.  ...
(Date:4/19/2017)... 2017  New research provides evidence that an old drug ... a study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... Parkinson,s disease, the oral drug levodopa has long been considered ... as the disease progresses, the effects of the medication can ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... Splashtop ... Mirroring360 Pro . This new addition to the Mirroring360 product family combines device ... business. , Mirroring360 Pro enables educators, business professionals and individuals to stream or ...
(Date:4/25/2017)... ... April 25, 2017 , ... As President ... are preparing for how his administration could impact the employee benefits industry. James ... changes are most likely to make it through Congress. His discussion will focus ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients who would like to ... a fraction of the time as traditional braces – Wilckodontics®. Dr. Victoria Chen, ... offers this revolutionary treatment with or without a referral. , Wilckodontics is ...
(Date:4/25/2017)... ... 2017 , ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace ... help but be heartened by the industry’s current surge. But another thing that unifies ... smell.” At last they can simply, safely and effectively end their aroma anguish ...
(Date:4/25/2017)... Fl (PRWEB) , ... April 25, 2017 , ... There ... Memorial Regional Hospital, according to a special report in the May issue of Consumer ... its highest quality ranking for results achieved during and after coronary bypass and ...
Breaking Medicine News(10 mins):